Press release
February 18, 2014
Robotic-Assisted Coronary Angioplasty Procedures will be Highlighted During CRT2014 Conference in Washington, D.C.

Waltham, MA, February 18, 2014Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that in addition to a talk focusing on robotics in the future of the cath lab, cases submitted by users of its CorPath Vascular Robotics System have been accepted for presentation at the Cardiovascular Research Technologies (CRT) conference on February 22–25, 2014 in Washington, D.C.

The CorPath System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Dr. Giora Weisz, Chairman of Cardiology at Shaare Zedek Medical Center in Israel will discuss how this technology will fit into the “Cath Lab of the Future” while the cases accepted to the CRT conference discuss the current clinical use of CorPath.

Dr. Puneet Sharma, interventional cardiologist at Sanford Clinic in Aberdeen, S.D., had a case selected as an Interesting Case for the conference. Dr. Sharma’s case submission details the first robotic-assisted stent placement in acute heart-attack within the 90 minute door to balloon guideline.

“Having performed more than 30 robotic-assisted angioplasties using the CorPath System, it is clear that this technology has set a new standard in vascular procedures,” said Dr. Ronald Caputo, Director of Cardiac Services and Cardiology Research at St. Joseph’s Hospital in Syracuse, N.Y. “We continue to take advantage of CorPath’s measurement tools, improved control and visualization enabling the interventional cardiologist to provide the ultimate quality of care that we strive to deliver to patients.”

The CorPath System enables precisely controlled, robotic-assisted angioplasties while the physician is seated in a lead-lined interventional cockpit protected from radiation exposure. CorPath enables the cardiologist to advance stents and guidewires millimeter-by-millimeter via a joystick.

“Our facility became the first hospital to perform a robotic angioplasty for a patient with an acute heart attack well within the national guidelines of 90 minutes,” noted Dr. Sharma. “Using the CorPath System, I was able to restore blood flow to the patient’s heart within 68 minutes of his arrival.”

Dr. Ron Waksman, Director of CRT and Associate Director, Division of Cardiology at the MedStar Washington Hospital Center and Director of Experimental Angioplasty and Emerging Technologies for the Cardiovascular Research Institute (CRI) at MedStar Washington Hospital Center said, “Robotics have the potential to revolutionize the cath lab. These cases are great examples of how our colleagues are already utilizing the technology to improve their practices. We felt that it is important to highlight this technology at CRT, one of the premier interventional cardiology meetings in the United States.”

“Cases like those submitted by Dr. Sharma highlight the increased acceptance and use of robotic technology in performing coronary angioplasty procedures,” said David Handler, CEO of Corindus. “CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements, reduced readmissions and other costs associated with improper stent placement.”

The CorPath system can be seen throughout the CRT conference in the following settings:

  • Dr. Weisz’s presentation can be seen Tuesday, February 25 at 2:10 in Palladian Room during the Cardiovascular Innovations session.
  • Dr. Sharma’s submission will be presented online at
  • Come see us at booth #102 for a hands-on demo with the CorPath through the conference.
About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
close the window

Please complete the form below in order to download the content.

close the window

Please complete the form below in order to download the content.

close the window

Please fill out this brief form to subscribe to our email newsletter. By submitting this form, I consent to receive email communications from Corindus.

close the window

Please complete the form below and a member of our Clinical team will contact you.

close the window

Please complete the form below in order to download the content.

close the window

The page you wish to view contains content that is not available in all regions. Please select your region.

close the window